CN109232539B - 一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 - Google Patents
一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 Download PDFInfo
- Publication number
- CN109232539B CN109232539B CN201811193237.0A CN201811193237A CN109232539B CN 109232539 B CN109232539 B CN 109232539B CN 201811193237 A CN201811193237 A CN 201811193237A CN 109232539 B CN109232539 B CN 109232539B
- Authority
- CN
- China
- Prior art keywords
- quinazoline
- schiff base
- bis
- preparation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002262 Schiff base Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- -1 aryl dialdehyde Chemical compound 0.000 claims description 19
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 8
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 125000005551 pyridylene group Chemical group 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract description 6
- 150000004753 Schiff bases Chemical group 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 6
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- IZALUMVGBVKPJD-UHFFFAOYSA-N benzene-1,3-dicarbaldehyde Chemical compound O=CC1=CC=CC(C=O)=C1 IZALUMVGBVKPJD-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PMWXGSWIOOVHEQ-UHFFFAOYSA-N pyridine-2,6-dicarbaldehyde Chemical compound O=CC1=CC=CC(C=O)=N1 PMWXGSWIOOVHEQ-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- KUCOHFSKRZZVRO-UHFFFAOYSA-N terephthalaldehyde Chemical compound O=CC1=CC=C(C=O)C=C1 KUCOHFSKRZZVRO-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811193237.0A CN109232539B (zh) | 2018-10-14 | 2018-10-14 | 一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811193237.0A CN109232539B (zh) | 2018-10-14 | 2018-10-14 | 一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109232539A CN109232539A (zh) | 2019-01-18 |
CN109232539B true CN109232539B (zh) | 2021-01-26 |
Family
ID=65052797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811193237.0A Active CN109232539B (zh) | 2018-10-14 | 2018-10-14 | 一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109232539B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106083740B (zh) * | 2016-06-03 | 2018-05-15 | 江苏开放大学 | 一种含1,2,3-三氮唑的4-苯胺基喹唑啉衍生物及制备方法 |
CN106045980B (zh) * | 2016-06-03 | 2017-11-03 | 江苏开放大学 | 一种喹唑啉衍生物及其制备方法 |
CN106478526B (zh) * | 2016-08-29 | 2019-02-05 | 陕西科技大学 | 一种喹唑啉酮席夫碱类化合物的合成方法 |
-
2018
- 2018-10-14 CN CN201811193237.0A patent/CN109232539B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109232539A (zh) | 2019-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Synthesis and antitumor activity of ureas containing pyrimidinyl group | |
CN110330474B (zh) | 芹菜素-二硫代氨基甲酸酯类衍生物制备及抗肿瘤应用 | |
CN111819177B (zh) | 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 | |
CN103265442A (zh) | 一类新型截短侧耳素衍生物及其制备方法和抗肿瘤用途 | |
CN105017259A (zh) | 含有三氟甲基的喹唑啉酮衍生物及其制备方法和应用 | |
CN108299398B (zh) | 一种具有抗肿瘤活性含咔唑的喹唑啉衍生物及其制药用途 | |
CN102702121A (zh) | 一种新化合物间羟基苯基四嗪二甲酰胺及制备和应用 | |
CN109232539B (zh) | 一类具有抗癌活性的双喹唑啉席夫碱衍生物及其制备与医药用途 | |
CN105713001B (zh) | 3,3’-二氢呋喃螺环氧化吲哚衍生物及其制备方法和应用 | |
CN109942499B (zh) | 喹唑啉衍生物及其制备方法和应用 | |
CN109627193B (zh) | 具有抗肿瘤作用的二芳基偶氮氧类化合物及其合成方法 | |
CN107698648B (zh) | 含胆甾醇的萘酰亚胺类衍生物及其合成和应用 | |
CN110790707A (zh) | 一种二硫代1,8-萘二酰亚胺类化合物及其制备方法和应用 | |
CN106831474B (zh) | 一种含α-芳基-α,β-二氨基酸酯衍生物及其合成方法和应用 | |
CN102584734B (zh) | 3,6-二甲基-1,2,4,5-四嗪-1,4-二甲酰胺类衍生物及制备和应用 | |
CN110483465B (zh) | 染料木素桥连哌嗪类衍生物合成方法及其抗肿瘤方向应用 | |
CN109160902B (zh) | 一种用于治疗肿瘤的不对称双喹唑啉席夫碱衍生物及其制备与医药用途 | |
CN107311949B (zh) | 磺酰胺取代的芳基三嗪类化合物及其制备方法与应用 | |
CN109020883B (zh) | 一种3-氰基-2-氨基吡啶类衍生物及其制备方法与应用 | |
CN108148080B (zh) | 金属有机金(iii)配合物及其合成方法和应用 | |
CN104370796A (zh) | 一种醋酸巴多昔芬多晶型b的制备方法 | |
CN115433200B (zh) | 含苯并二氢吡喃-4-酮结构的四环化合物、合成方法及应用 | |
CN116063230B (zh) | 一类青藤碱1位取代衍生物及其制备方法和应用 | |
CN113563330B (zh) | 一类β-卡波林的3位衍生物及其制备方法和用途 | |
CN111072562B (zh) | 一种四氢异喹啉衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Xiaoqing Inventor after: Jiang Yahong Inventor after: Ma Lihua Inventor after: Su Longzhen Inventor after: Shi Xiaohui Inventor before: Ma Lihua Inventor before: Su Longzhen Inventor before: Shi Xiaohui |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210107 Address after: 201111 room e268, 2nd floor, building 3, 2118 Guanghua Road, Minhang District, Shanghai Applicant after: Shanghai Yaoda Biotechnology Co.,Ltd. Address before: Room 213, building 4, Fenghui business square, 158 Shanji Road, Yuanhe street, Xiangcheng District, Suzhou City, Jiangsu Province Applicant before: SUZHOU HUAZHEN MEDICAL TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231030 Address after: 201114 room 304-9, building 10, No. 2168, Chenhang highway, Minhang District, Shanghai Patentee after: Shanghai Yaoda Biotechnology Co.,Ltd. Patentee after: Lingyao Biotechnology (Shanghai) Co.,Ltd. Address before: 201111 room e268, 2nd floor, building 3, 2118 Guanghua Road, Minhang District, Shanghai Patentee before: Shanghai Yaoda Biotechnology Co.,Ltd. |